2-47412522-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.754C>T(p.Gln252*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000685 in 1,459,436 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1459436Hom.: 0 Cov.: 29 AF XY: 0.00000138 AC XY: 1AN XY: 726224
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This premature translational stop signal has been observed in individual(s) with Lynch syndrome-related cancer (PMID: 7585065, 15849733, 16807412). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 91196). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln252*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q252* pathogenic mutation (also known as c.754C>T), located in coding exon 4 of the MSH2 gene, results from a C to T substitution at nucleotide position 754. This changes the amino acid from a glutamine to a stop codon within coding exon 4. This alteration has been reported in multiple individuals with either early onset colorectal cancer or meeting Bethesda criteria (Barnetson RA et al. N. Engl. J. Med. 2006 Jun;354(26):2751-63; Farrington SM et al. Am. J. Hum. Genet. 1998 Sep; 63(3):749-59; Mangold E et al. Int. J. Cancer 2005 Sep;116(5):692-702; Liu Be et al. Nat. Med. 1995 Apr;1(4):348-52). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at